

EBMT Transplantation and Cellular Therapy in Myeloid Malignancies Meeting

Paris, France | 21-22 January 2027



Acute
Leukaemia
ALWP



Chronic
Malignancies
CMWP

Thursday, 21 January 2027

09:00 – 13:00	Scientific Business Meetings
14:00 – 16:00	Session I: Novel insights on allo-HCT indications and management
	Chairs:
14:00 – 14:15	Welcome and Introduction
14:15 – 14:35	Allo-HCT Recommendation in Non-Classical MPN and MDS/MPN
14:35 – 14:55	Defining Remission and Relapse in MDS/MPN Overlaps
14:55 – 15:15	Update on Allo-HCT Indications in AML
15:15 – 15:35	Update on Allo-HCT for ALL in CR1
15:35 – 15:45	Case presentation Slot 1
15:45 – 15:55	Case presentation Slot 2
15:55 – 16:00	Discussion
16:00 – 16:30	Coffee Break
16:30 – 17:15	Industry Symposium Slot
17:15 – 18:45	Session II: Session II: Allo-HCT in high-risk AML or MDS
	Chairs:
17:15 – 17:35	Role of Allo-HCT in High-Risk AML
17:35 – 17:55	Upfront versus Cyto-reduction before Transplant in MDS
17:55 – 18:15	Maintenance Post Allo in AML
18:15 – 18:25	Case presentation Slot 3
18:25 – 18:35	Case presentation Slot 4
18:35 – 18:45	Discussion

To be announced
To be announced
All

To be announced
To be announced
All

EBMT Transplantation and Cellular Therapy in Myeloid Malignancies Meeting

Paris, France | 21-22 January 2027



Acute
Leukaemia
ALWP



Chronic
Malignancies
CMWP

Friday, 22 January 2027

09:00 – 10:30 Session III: CAR-T Cell Therapy for ALL and AML/MDS: Where Do We Stand?

Chairs:

09:00 – 09:20 Up to Date on CAR-T Therapy for AML and High-Risk MDS

09:20 – 09:40 Calreticulin-Targeted CAR T-cell Therapy in MPN

09:40 – 10:00 Update CAR-T in ALL

10:00 – 10:10 Case presentation Slot 5

10:10 – 10:20 Case presentation Slot 6

10:20 – 10:30 Discussion

To be announced

To be announced

All

10:30 – 11:30 Keynote Lecture

Chair:

10:30 – 11:15 Nobilities in Myelofibrosis

11:15 – 11:30 Q&A

All

11:30 – 12:00 Coffee Break

12:00 – 12:45 Industry Symposium Slot

12:45 – 14:15 Session IV: Post Allo-HCT Management in BCR::ABL1 mutated leukaemias

Chairs:

12:45 – 13:10 EBMT-Lead Expert Recommendation on CML Management Post Allo-HCT

13:10 – 13:35 Optimizing Management of Ph+ ALL after Transplant and CAR-T Cells

13:35 – 13:45 Case presentation Slot 7

13:45 – 13:55 Case presentation Slot 8

13:55 – 14:15 Discussion

To be announced

To be announced

All

14:15 – 14:45 Coffee Break

14:45 – 16:50 Session V: Controversies

Chairs:

14:45 – 15:40 Is It Time for PTCy to Replace ATG as the Standard GVHD Prophylaxis in Myeloid Malignancies?

14:45 – 14:55 Case presentation Slot 9

To be announced

14:55 – 15:15 Yes

15:15 – 15:35 No

15:35 – 15:40 Q&A

All

15:45 – 16:40 Second Transplantation or DLI in Patients with MDS or AML Relapsing after Transplantation?

15:45 – 15:55 Case presentation Slot 10

To be announced

15:55 – 16:15 Second allo

16:15 – 16:35 DLI

16:35 – 16:40 Q&A

All

16:40 – 16:50 Take Home Messages & Closing Remarks

For further information, please get in contact with education.events@ebmt.org